Link to abstract (which has a link to the PDF) instead of to the prel…

…iminary PDF which is what I generally do elsewhere on this page, too. Consider linking to doi.org though maybe?
ljl-covid · Mar 9, 2021 · cb75bd3 · cb75bd3
1 parent 56972a4
commit cb75bd3
Showing 1 changed file with 1 addition and 1 deletion.
diff --git a/README.md b/README.md
@@ -299,7 +299,7 @@ Note that the WHO will generally be unable to make statements that their more pr
 * [The Vaccine Tightrope](https://blogs.sciencemag.org/pipeline/archives/2020/10/21/the-vaccine-tightrope) by Derek Lowe analyzes the problem of vaccines being deployed before trials for other vaccines are over, as well as of providing placebo arms with the actual vaccine before the full trial length of two years is completed, with ethical and practical repercussions on participants
 * [mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants](https://www.nature.com/articles/s41586-021-03324-6) reports on immune response of recipients of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines and notes that activity of their serum against SARS-CoV-2 variants encoding E484K or N501Y or the K417N:E484K:N501Y combination was reduced by a small but significant margin
 * [Effectiveness of First Dose of COVID-19 Vaccines Against Hospital Admissions in Scotland: National Prospective Cohort Study of 5.4 Million People](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3789264) shows that the Pfizer/BioNTech (BNT162b2) vaccine was associated with a vaccine effect of 85% against hospitalization at 28-34 days post-vaccination, while the effect of the Oxford/Astrazeneca (ChAdOx1) vaccine was 94%, although the age cohorts in the two vaccines were different, and the efficacy against hospitalization was similar for the two vaccines, at 81%, when looking at people over 80
-* [Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7](https://www.nature.com/articles/s41586-021-03398-2_reference.pdf) unfortunately has worse findings, B.1.351 in particular being worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely owing to an E484K mutation, and it is very resistant to neutralizatio by both convalescent plasma and sera from people who received the Pfeizer and Moderna vaccines, by around 10 times
+* [Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7](https://www.nature.com/articles/s41586-021-03398-2) unfortunately has worse findings, B.1.351 in particular being worrisome in that this variant is not only refractory to neutralization by most NTD mAbs but also by multiple individual mAbs to the receptor-binding motif on RBD, largely owing to an E484K mutation, and it is very resistant to neutralizatio by both convalescent plasma and sera from people who received the Pfeizer and Moderna vaccines, by around 10 times
 * [FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system](https://www.medrxiv.org/content/10.1101/2021.02.15.21251623v2) is a preprint that analyzes more than 60000 individuals at Mayo Clinic, dividing them into a vaccinated cohort (with Pfizer/BioNTech or Moderna) and an unvaccinated one, and retrospectively concluding there was 88.7% efficacy in preventing infection, i.e. a positive RT-PCR test at all, and hence likely also contagiousness, as opposed to just symptomatic cases, which was the benchmark of most of the vaccine trials
 * [Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00528-6/fulltext#coronavirus-linkback-header) tries to make sense of the confusing dosing issues with the Oxford/Astrazeneca (ChAdOx1) vaccine, and provides some tentative evidence in favor of the UK choice of delaying the booster shot to 12 weeks after the initial shot